Beximco Pharma Launches Generic Molnupiravir In Bangladesh To Treat Symptomatic COVID-19

-- November 9, 2021

Source: Nasdaq

(RTTNews) - Beximco Pharmaceuticals Limited (BXP.L) announced the launch of generic molnupiravir, an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme and Ridgeback Biotherapeutics. Beximco Pharma's generic version of molnupiravir will be marketed as Emorivir. It will initially be launched in Bangladesh.

Beximco Pharma noted that molnupiravir is the world's first oral antiviral drug to treat COVID-19. Molnupiravir was approved by the UK's Medicines and Healthcare products Regulatory Agency on 4 November 2021.

Based on current infection rates in Bangladesh, Beximco Pharma does not expect a material impact on full-year revenues.



  • A specialized institute that works for the holistic development of children with special educational needs through different programs
  • Include early childhood development programs (ECD), special schooling, therapeutic interventions, medical and neuro-developmental assessment, leisure time and co-curricular activities, training for the teachers, parents and integrated services

Other CSR Initiatives

... ...
  • Charity contributions through the Gono Sahajjo Songstha (GSS) for the educational sector for the unprivileged
  • Free drugs during natural calamities and distribution of clothing during winter
  • As part of BEXIMCO Group’s focus on society development, Fazlur Rahman Foundation has established a project called "FRF Diagnostic Centre". The project provides health screening services for Beximco Pharmaceuticals and Beximco Antibiotics Industries employees.
  • Sponsoring events and national sport stars and teams
  • Official sponsor of the Bangladesh National Cricket team for the ICC Cricket World Cup 2011
  • Official sponsor of the FIFA friendly match between Argentina and Nigeria held in September, 2011